In the current market session, Intuitive Surgical Inc. (NASDAQ:ISRG) share price is at $446.32, after a 0.20% drop. Over the past month, the stock went up by 0.11%, but over the past year, it actually fell by 7.92%. With good short-term performance like this, and questionable long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio.Intuitive Surgical P/E Ratio Analysis in Relation to Industry PeersThe P/E ratio is used by long-term shareholders to ...

Group 1 - The article provides a market analysis focusing on Intuitive Surgical Inc and the Health Care Select Sector SPDR® Fund, highlighting their performance and investment potential [1] - Intuitive Surgical Inc is noted for its innovative surgical systems, which have contributed to its strong market position and growth prospects [1] - The Health Care Select Sector SPDR® Fund is analyzed in terms of its overall performance in the healthcare sector, reflecting trends and investor sentiment [1] Group 2 - The analysis includes key financial metrics and performance indicators for both Intuitive Surgical Inc and the Health Care Select Sector SPDR® Fund, offering insights into their valuation and market trends [1] - The article discusses the competitive landscape within the healthcare industry, emphasizing the importance of technological advancements and regulatory factors affecting investment decisions [1] - Future growth opportunities for Intuitive Surgical Inc are identified, particularly in expanding its product offerings and market reach [1]

Key Takeaways ISRG gained 510(k) clearance for SP in transanal colorectal excision and resection.ISRG's SP procedures surged 88% YoY, led by 112% growth in Korea and steady gains in Europe and Japan.ISRG's SP utilization rose 30%, showing expanding applications per installed ISRG system.Intuitive Surgical’s (ISRG) second-quarter 2025 update placed a spotlight on the expanding clinical scope of its Single-Port (SP) platform, with colorectal surgery emerging as a key frontier. The company secured 510(k) clear ...

Investors with a lot of money to spend have taken a bearish stance on Intuitive Surgical (NASDAQ:ISRG).And retail traders should know.We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ISRG, it often means somebody knows something is about to happen.So how do we know what these investors just did? Today, Benzinga's options scann ...

The medical sector in the United States has been heavily affected by a bearish cycle, driven by scandals surrounding the GLP-1 drugs used in weight loss solutions for consumers. As more companies are exposed to the manufacturing and distribution of these drugs, even some unrelated names have been dragged down by this broader sentiment, creating massive opportunities for those who are bold enough to look into the space. Intuitive Surgical TodayISRGIntuitive Surgical$439.20 -8.04 (-1.80%) 52-Week Range$425.0 ...

Key Points Intuitive Surgical is looking at a vast long-term opportunity in its market. The company's moat practically guarantees it will remain a leader in the field. This strong position in its industry can allow it to overcome the challenges it faces. 10 stocks we like better than Intuitive Surgical › Intuitive Surgical (NASDAQ: ISRG), which specializes in the robotic-assisted surgery market, has had a difficult year. The company is facing a significant threat from the impact of President Donal ...

Key Points Intuitive Surgical's stock has been in a free fall since the company reported earnings a few months ago. Investors appear to be worried about the impact that tariffs will have on both its top and bottom lines. 10 stocks we like better than Intuitive Surgical › Investing in future technologies is what makes Intuitive Surgical (NASDAQ: ISRG) an intriguing long-term buy. Its robotic-assisted da Vinci surgical systems could revolutionize the healthcare sector in the years to come. However, ...

Core Insights - The article discusses the 12 best healthcare stocks to buy and hold for five years, highlighting the role of AI in improving healthcare services and addressing insurance denials [1][4]. Group 1: AI in Healthcare - Dr. Warris Bokhari's platform utilizes AI to appeal health insurance denials for approximately 70 autoimmune diseases, addressing a significant issue where 850 million denials occur annually in the U.S. [2][3]. - The platform was launched on October 2, 2024, and aims to assist patients in navigating care denials by generating appeal letters based on healthcare plans [4]. Group 2: Stock Selection Methodology - The selection of the top healthcare stocks was based on criteria including EPS growth of over 10% in the past five years, an expected EPS growth rate of at least 20% over the next five years, and a forward PE ratio greater than 20 [6]. - The final ranking of stocks was influenced by the number of hedge fund holders as tracked by the Insider Monkey database as of Q2 2025 [6][7]. Group 3: Company Highlights - **Intuitive Surgical, Inc. (NASDAQ:ISRG)**: Pioneered robotic-assisted minimally invasive surgery with its da Vinci systems, which are used globally. The company introduced advanced software features for its da Vinci 5 system in September 2025, enhancing surgical capabilities [9][10]. - **Doximity, Inc. (NYSE:DOCS)**: A leading healthcare technology stock that completed the acquisition of Pathway Medical, enhancing its AI-driven tools. The company reported a 15% year-over-year revenue increase, reaching $145.9 million for the quarter ending June 30, 2025 [13][15]. - **Penumbra, Inc. (NYSE:PEN)**: A leader in thrombectomy and vascular intervention technologies, recently introduced the Ruby XL System and the Lightning Bolt 6X device, expanding its product offerings and market reach [16][18].

Market Overview - The global surgical robotics market was valued at approximately $4.31 billion in 2024 and is projected to reach $9.6 billion by 2033, at a CAGR of 9.3% [2] - North America holds about 39.6% of the worldwide market share in 2025 [2] Company Insights: Intuitive Surgical (ISRG) - Intuitive Surgical maintains nearly 60% of the global market share, supported by a strong recurring revenue stream from its installed base [3] - The da Vinci Surgical System has evolved through five generations, integrating AI and advanced technologies, enhancing surgical precision and expanding its applicability [4] - The latest model, da Vinci 5, has seen 180 placements by mid-2025, with nearly 700 systems installed globally [5] - Recurring revenues from instruments and digital services account for 85% of total revenues, with per-procedure spend remaining steady at nearly $1,800 [6] - The Ion endoluminal platform is emerging as a growth driver, with over 900 systems installed and a 50% year-over-year increase in procedures [7] - Intuitive Surgical has raised its 2025 growth outlook to 15.5-17% due to rising adoption of da Vinci 5 and Ion's penetration [8] Company Insights: Zimmer Biomet (ZBH) - Zimmer Biomet is focusing on its expanding knee portfolio and innovation strategy to strengthen its position in the musculoskeletal market [9] - The company's ROSA Robotic Platform and cementless knees are driving steady growth, with a 150 basis point improvement in sequential growth in 2025 [10] - The Persona Revision Knee has surpassed 100 accounts in Europe, with expectations for accelerated momentum [11] - Zimmer Biomet's strategic plan includes investing in leadership, operational excellence, and innovation, supported by acquisitions [12] - The company has shown steady gains with 1.8% growth in knees, 4.0% in hips, and 4.9% in S.E.T during the second quarter [13] Price Performance and Valuation - Shares of Intuitive Surgical have declined 15.5% year-to-date, while Zimmer Biomet's stock is down 12.9% [14] - Intuitive Surgical's valuation has declined but still trades above the industry average, while Zimmer Biomet trades at a significant discount [18] - Zimmer Biomet currently carries a Zacks Rank 2 (Buy), while Intuitive Surgical has a Zacks Rank 4 (Sell), indicating a better investment opportunity in Zimmer Biomet [24] Conclusion - Both companies are positioned to benefit from the rising demand for robotic surgery, particularly in the U.S. market [23] - Zimmer Biomet offers a more attractive valuation compared to Intuitive Surgical, which is trading above its industry's valuation [23]

With a market cap of $158.1 billion, Intuitive Surgical, Inc. (ISRG) develops, manufactures, and markets innovative robotic-assisted surgical systems and related products that enable minimally invasive care. Its flagship offerings include the da Vinci Surgical System and the Ion endoluminal system, supported by a comprehensive portfolio of instruments, accessories, services, and digital solutions. The Sunnyvale, California-based company is expected to announce its fiscal Q3 2025 results on Thursday, Oct. ...